Skip to main content

California Institute for Regenerative Medicine — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

49
Companies
$676.9M
Total invested
$14.1M
Avg. check
19
Industries
Biotechnology 22Health Care 16Therapeutics 9Medical 9Biopharma 4Life Science 3+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 49
Angiocrine Bioscience
September 2025

Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.

Biotechnology · New York$2.1M Undisclosed
Greenstone Biosciences
September 2023

Greenstone Biosciences is a drug discovery platform that accelerates the development of effective therapies for patients.

Biotechnology · Palo Alto$2.8M Grant
AIVITA Biomedical
August 2022

AIVITA Biomedical is is a medicine company develops commercial and clinical stage programs utilizing curative and regenerative medicines.

Biotechnology · Irvine$6.0M Venture - Series Unknown
Nexcella
July 2024

Nexcella Utilize cell therapies to create safe and effective medicines for oncology and other conditions, improving patient outcomes.

Biotechnology · Los Angeles$8.0M Grant
ImmunoVec
July 2026

ImmunoVec develops gene therapy treatments to cure terminal genetic diseases of the immune system.

Biotechnology · Santa Monica$12.7M Venture - Series Unknown
Rejuvenate Bio
June 2026

Rejuvenate Bio is a biotechnology company that develops therapies to reverse aging and treat age-related diseases.

Biotechnology · San Diego$6.0M Venture - Series Unknown
Aspera Biomedicines
May 2025

Aspera Biomedicines is a space-accelerated biotechnology company pioneering therapies that target cancer stem cells.

Biopharma · La Jolla$3.2M Grant
Mahzi Therapeutics
May 2025

Mahzi Therapeutics is a health care and biotechnology company.

Biopharma · San Mateo$4.0M Grant
Blue Gen Therapeutics Foundation
May 2025

Blue Gen Therapeutics Foundation is a non-profit clinical-stage biotech organization.

Biotechnology · Sacramento$4.7M Grant
Luxa Biotechnology
May 2024

Luxa Biotechnology is a clinical-stage biotechnology firm developing a unique adult RPE stem cell (RPESC) therapy for dry AMD.

Clinical Trials · Fort Lee$4.0M Grant
Denovo Biopharma
April 2024

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development.

Biopharma · San Diego$11.8M Grant
Anova Enterprises
April 2024

Anova Enterprises accelerates clinical development of promising therapeutics through improved access, collaboration and data.

Clinical Trials · Chicago$11.8M Grant
AcuraStem
April 2026

AcuraStem harnesses human, patient-specific in vitro cell models and assays to develop cures and improve diagnoses in disorders of the CNS.

Artificial Intelligence (AI) · Pasadena$7.5M Grant
Combangio
April 2023

Combangio is a clinical-stage biotechnology company focused on developing regenerative biotherapeutics.

Biotechnology · California$15.0M Grant
Calidi Biotherapeutics
March 2026

Calidi Biotherapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer.

Biotechnology · San Diego$6.0M Post-IPO Equity
Tachyon Therapeutics
March 2023

Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.

Biotechnology · San Francisco$11.6M Series A
Mustang Bio
February 2025

Mustang Bio is a clinical-stage biopharmaceutical company .

Biotechnology · New York$8.0M Post-IPO Equity
Navega Therapeutics
February 2025

Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases.

Biopharma · San Diego$4.0M Grant
Genascence
February 2023

Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases

Biotechnology · Palo Alto$11.6M Grant
Tr1x
October 2025

Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.

Biotechnology · San Diego$50.0M Venture - Series Unknown
Lutris Pharma
January 2025

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

Biotechnology · Tel Aviv-yafo$30.0M Venture - Series Unknown
Kenai Therapeutics
February 2024

Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.

Biotechnology · San Diego$82.0M Series A
Cytonus Therapeutics
November 2023

Cytonus is a biotech company combining AI-driven drug discovery together with a class defining drug-delivery platform called the Cargocyte

Biotechnology · Carlsbad$11.7M Series A
Entos Pharmaceuticals
January 2026

Entos Pharmaceuticals is a clinical-stage biotech company developing genetic medicines with its Fusogenix PLV drug delivery platform.

Biotechnology · EdmontonGrant

Where California Institute for Regenerative Medicine invests

Biotechnology22
Health Care16
Therapeutics9
Medical9
Biopharma4
Life Science3

About California Institute for Regenerative Medicine's portfolio

How many companies has California Institute for Regenerative Medicine invested in?

California Institute for Regenerative Medicine has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does California Institute for Regenerative Medicine invest in?

California Institute for Regenerative Medicine's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 19 different industry categories.

What is California Institute for Regenerative Medicine's largest investment?

Among tracked funding rounds, Kenai Therapeutics received $82.0M in a Series A round. California Institute for Regenerative Medicine's total known invested capital is $676.9M.

What is the average investment size for California Institute for Regenerative Medicine?

California Institute for Regenerative Medicine's average investment size is $14.1M across its portfolio of 49 companies.

What are California Institute for Regenerative Medicine's most recent investments?

Recent California Institute for Regenerative Medicine portfolio additions include Angiocrine Bioscience, Greenstone Biosciences, AIVITA Biomedical, Nexcella, ImmunoVec. These companies were founded in 2020 or later.

Reach the founders behind these 49 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →